Biotech said at an investor relations event that the company will work hard to obtain approval for BAT2206 to be listed in major markets in the second half of this year and early next year. The first phase III WAMD study of BAT5906 was revealed at the end of the second quarter of 2025. DME clinical trials are underway. The company already has plans to conduct registered clinical studies on CNV and CRVO, which are in the preparation stage. Subcutaneous development of tocilizumab and European cooperation with tocilizumab are in progress, and the company will promote the sale of approved intravenous drugs in Europe as soon as possible. The company is stepping up preparations for the BAT8006 clinical program, and it is estimated that the enrollment of participants will begin this month.

Biotech said at an investor relations event that the company will work hard to obtain approval for BAT2206 to be listed in major markets in the second half of this year and early next year. The first phase III WAMD study of BAT5906 was revealed at the end of the second quarter of 2025. DME clinical trials are underway. The company already has plans to conduct registered clinical studies on CNV and CRVO, which are in the preparation stage. Subcutaneous development of tocilizumab and European cooperation with tocilizumab are in progress, and the company will promote the sale of approved intravenous drugs in Europe as soon as possible. The company is stepping up preparations for the BAT8006 clinical program, and it is estimated that the enrollment of participants will begin this month.